Ecopetrol Says Guillermo García Realpe Voluntarily Resigned From His Role As Chairman Of Board
ReutersAug 19, 2025 10:54 PM
Aug 19 (Reuters) - Ecopetrol SA ECO.CN:
ECOPETROL SA - GUILLERMO GARCÍA REALPE VOLUNTARILY RESIGNED FROM HIS ROLE AS CHAIRMAN OF BOARD
ECOPETROL SA - ELECTED MÓNICA DE GREIFF LINDO AS NEW CHAIRWOMAN EFFECTIVE AUGUST 20, 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
BHP’s 2025 Playbook: Turning Profit Dips into Strategic Wins
TradingKey - On August 18, 2025, BHP Group announced its full-year results for the 2025 fiscal year. Despite an 8% year-on-year revenue decline to $51.3 billion and a 26% significant drop in underlying attributable profit, which reflects core business performance, to $10.2 billionTradingKey
12 hours ago
U.S. Stock Market Risk Assessment: Learning from History, Mid-Term Outlook Remains Secure
We argue that the Federal Reserve’s monetary policy is the most critical factor influencing the stock market.TradingKey
Mon, Aug 18
Powell's Jackson Hole Speech: For U.S. Stocks, Hawk or Dove Signal Could Be a Lose-Lose?
TradingKey - As U.S. inflation and labor market data show signs of rebalancing, Treasury traders and Wall Street banks have largely priced in a rate cut at the September FOMC meeting — the first of 2025. Yet both a more dovish-than-expected tone and a potential surprise hawkish signal from Fed ChairTradingKey
Mon, Aug 18
Eurozone Q2 GDP Commentary: Will the Euro's Upward Momentum Persist?
TradingKey - On 14 August 2025, Eurostat published Q2 GDP figures, revealing a drop in the Eurozone's quarter-on-quarter growth from 0.6% in the first quarter to 0.1%. Consequently, annual growth eased from 1.5% to 1.4%. The slowdown primarily stems from the diminishing boost from European...TradingKey
Mon, Aug 18
From Ozempic to Wegovy: Growth and Risks Behind Novo Nordisk’s Q2 Performance
TradingKey - Novo Nordisk achieved revenue of $11.67 billion in Q2 of the 2025 fiscal year, a 19% increase year-over-year, but it fell short of market expectations. Growth was primarily driven by strong performance in obesity care and rare diseases.TradingKey
Thu, Aug 7
